Yanmin Hu

Yanmin Hu

Auto-generated profile, based on publicly available information

Yanmin Hu

Institute for Infection and Immunity, St George's, University of London, London, United Kingdom

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2002 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
ACAnthony Coates
Anthony Coates
YHYanmin Hu
Yanmin Hu
RBRichard Bax
Richard Bax
CPClive Page
Clive Page

6 April 2011 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
ACAnthony Coates
Anthony Coates
GHGerry Halls
Gerry Halls
YHYanmin Hu
Yanmin Hu

31 December 2015 in mBio
Verified
Journal Article
Open access
PDF file
Egija ZauraEgija Zaura
Egija Zaura
BBBernd W Brandt
Bernd W Brandt
MMM Joost Teixeira De Mattos
M Joost Teixeira De Mattos
MBMark J Buijs
Mark J Buijs
MCMartien P M Caspers
Martien P M Caspers
WCWim Crielaard
Wim Crielaard
Due to the spread of resistance, antibiotic exposure receives increasing attention. Ecological consequences for the different niches of individual microbiomes are, however, largely ignored. Here, we report the effects of widely used antibiotics (clindamycin, ciprofloxacin, amoxicillin, and minocycline) with different modes of action on the ecology of both the gut and the oral microbiomes in 66 healthy adults from the United Kingdom and Sweden in a two-center randomized placebo-controlled clinical trial. Feces and saliva were collected at baseline, immediately after exposure, and 1, 2, 4, and 12 months after administration of antibiotics or placebo. Sequences of 16S rRNA gene amplicons from all samples and metagenomic shotgun sequences from selected baseline and post-antibiotic-treatment sample pairs were analyzed. Additionally, metagenomic predictions based on 16S rRNA gene amplicon data were performed using PICRUSt. The salivary microbiome was found to be significantly more robust, whereas the antibiotics negatively affected the fecal microbiome: in particular, health-associated butyrate-producing species became strongly underrepresented. Additionally, exposure to different antibiotics enriched genes associated with antibiotic resistance. In conclusion, healthy individuals, exposed to a single antibiotic treatment, undergo considerable microbial shifts and enrichment in antibiotic resistance in their feces, while their salivary microbiome composition remains unexpectedly stable. The health-related consequences for the gut microbiome should increase the awareness of the individual risks involved with antibiotic use, especially in a (diseased) population with an already dysregulated microbiome. On the other hand, understanding the mechanisms behind the resilience of the oral microbiome toward ecological collapse might prove useful in combating microbial dysbiosis elsewhere in the body. IMPORTANCE Many health care professionals use antibiotic prophylaxis strategies to prevent infection after surgery. This practice is under debate since it enhances the spread of antibiotic resistance. Another important reason to avoid nonessential use of antibiotics, the impact on our microbiome, has hardly received attention. In this study, we assessed the impact of antibiotics on the human microbial ecology at two niches. We followed the oral and gut microbiomes in 66 individuals from before, immediately after, and up to 12 months after exposure to different antibiotic classes. The salivary microbiome recovered quickly and was surprisingly robust toward antibiotic-induced disturbance. The fecal microbiome was severely affected by most antibiotics: for months, health-associated butyrate-producing species became strongly underrepresented. Additionally, there was an enrichment of genes associated with antibiotic resistance. Clearly, even a single antibiotic treatment in healthy individuals contributes to the risk of resistance development and leads to long-lasting detrimental shifts in the gut microbiome.

2 January 2020 in Expert Review of Anti-infective Therapy
Verified
Journal Article
Closed access
ACAnthony Coates
Anthony Coates
YHYanmin Hu
Yanmin Hu
JHJames Holt
James Holt
PYPamela Yeh
Pamela Yeh
Introduction: Anti-Microbial Resistance (AMR) is a pandemic which threatens modern medicine. There is a lack of effective drug treatment due to the slow pace, high cost and low achievable sales prices of new antibiotic monotherapies. A new hope comes in the shape of antibiotic combination therapy, which although used by mother nature, is under-explored and could provide the solution to AMR. Areas covered: We performed a search of Pubmed and Medline using the keywords “combination therapy”, “antimicrobial resistance” for articles between 1930 and 2019, as supplemented with other relevant references to our knowledge. We will review the theoretical considerations for combination development and examine the existing and future clinical indications of combination therapies. We will discuss the potential of antibiotic combinations to provide therapeutic synergy, rejuvenating the effectiveness of old antibiotics to which the bacteria had developed resistance previously. We will examine the current thinking and evidence on resistance reduction using combination therapies, with a review on toxicity and drug-drug antagonism. Expert opinion: Antibiotic combination therapy, exploiting synergies, old-drug rejuvenation and resistance reduction could provide the solution to AMR. The number of pharmaceutical companies in this area is likely to expand, bringing promising combinations to the bedside, to save millions of lives worldwide.

1 February 2003 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
YHYanmin Hu
Yanmin Hu
ACAnthony Coates
Anthony Coates
DMDenis A. Mitchison
Denis A. Mitchison
The bactericidal activities of ciprofloxacin, ofloxacin, levofloxacin, moxifloxacin, and gatifloxacin were tested in three models of rifampin-tolerant Mycobacterium tuberculosis persisters. Model 1 was a 100-day-old, unshaken, anaerobically adapted culture in which serial dilutions of the quinolones were incubated for 5 days and CFU counts were then done In models 2 and 3, 100 mg of rifampin/liter was added to the 100-day culture for 5 or 7 days to produce tolerant organisms that did not grow on plates; the rifampin was then washed off, fresh medium was added to allow recovery of growth on plates, and the culture was incubated for 7 days before CFU counts. In model 2, the quinolones were added after rifampin had been washed off, whereas in model 3 the quinolones were added to the cultures containing rifampin. In models 1 and 2, ciprofloxacin had the least bactericidal activity, ofloxacin and levofloxacin had greater activities, and moxifloxacin and gatifloxacin had the greatest activities. In model 3, ofloxacin had no detectable activity whereas moxifloxacin killed about log 10 0.279 CFU of the persisters per ml at concentrations attainable in lesions; isoniazid had virtually no activity. These findings predict that ofloxacin will not be found to have effective sterilizing activity in clinical studies now planned whereas moxifloxacin will be able to shorten treatment.

15 November 2000 in Journal of Bacteriology
Verified
Journal Article
Closed access
PDF file
YHYanmin Hu
Yanmin Hu
JMJoseph A. Mangan
Joseph A. Mangan
JDJasvir Dhillon
Jasvir Dhillon
KSKath M. Sole
Kath M. Sole
DMDenis A. Mitchison
Denis A. Mitchison
ACAnthony Coates
Anthony Coates
Mycobacterium tuberculosis can persist in an altered physiological state for many years after initial infection, and it may reactivate to cause active disease. An analogous persistent state, possibly consisting of several different subpopulations of bacteria, may arise during chemotherapy; this state is thought to be responsible for the prolonged period required for effective chemotherapy. Using two models of drug-induced persistence, we show that both microaerophilic stationary-phase M. tuberculosis treated with a high dose of rifampin in vitro and pyrazinamide-induced persistent bacteria in mice are nonculturable yet still contain 16S rRNA and mRNA transcripts. Also, the in vitro persistent, plate culture-negative bacteria incorporate radioactive uridine into their RNA in the presence of rifampin and can rapidly up-regulate gene transcription after the replacement of the drug with fresh medium and in response to heat shock. Our results show that persistent M. tuberculosis has transcriptional activity. This finding provides a molecular basis for the rational design of drugs targeted at persistent bacteria.